The QuANTUM-First trial, published early in 2023, associated quizartinib (Vanflyta, Daiichi-Sankyo) with longer overall survival (OS) than placebo on top of conventional chemotherapy in newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML). A new analysis shows that negative FLT3-ITD-specific minimum residual disease (MRD) is an important predictor of outcome, including OS.
“These findings demonstrate the prognostic utility of FLT3-ITD-specific MRD measurements in the